Literature DB >> 11872993

Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy.

Grace McComsey1, Duan-Jun Tan, Michael Lederman, Elizabeth Wilson, Lee-Jun Wong.   

Abstract

OBJECTIVE: To investigate the molecular mechanisms of nucleoside analogue reverse transcriptase inhibitor (NRTI)-associated mitochondrial dysfunction.
METHODS: Peripheral blood samples were collected from 10 healthy individuals, 10 HIV-infected, NRTI-treated patients with lipoatrophy, and four HIV-infected patients naive to all antiretrovirals. DNA was isolated from the leukocytes and the mitochondrial genome analyzed for DNA depletion, deletions and point mutations.
RESULTS: We were not able to detect mitochodrial DNA (mtDNA) depletion, deletions, or DNA rearrangements in any of the specimens, including one from a patient with fulminant lactic acidosis. A complete analysis of the entire mitochondrial genome by temporal temperature gradient gel electrophoresis revealed several nucleotide substitutions in blood mtDNA of several HIV infected patients.
CONCLUSION: We found no evidence for NRTI-associated mtDNA depletion or gross mtDNA mutations in leukocytes of HIV-infected patients, regardless of their treatment history. Thus, either NRTI-induced mutations in mtDNA are tissue-specific or alternatively, pre-existent mtDNA variations in HIV disease predispose to the development of clinically apparent mitochondrial dysfunction during NRTI therapy. The significance of mtDNA variations in the development of mitochondrial-related clinical conditions in HIV patients with or without NRTI therapy is to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872993     DOI: 10.1097/00002030-200203080-00001

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

1.  Peripheral Blood Mitochondrial DNA Copy Number Obtained From Genome-Wide Genotype Data Is Associated With Neurocognitive Impairment in Persons With Chronic HIV Infection.

Authors:  Todd Hulgan; Asha R Kallianpur; Yan Guo; Jill S Barnholtz-Sloan; Haley Gittleman; Todd T Brown; Ronald Ellis; Scott Letendre; Robert K Heaton; David C Samuels
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-01       Impact factor: 3.731

2.  Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status.

Authors:  Cecilia M Shikuma; Mariana Gerschenson; Dominic Chow; Daniel E Libutti; John H Willis; James Murray; Roderick A Capaldi; Michael Marusich
Journal:  AIDS Res Hum Retroviruses       Date:  2008-10       Impact factor: 2.205

3.  HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue.

Authors:  Caryn G Morse; Joachim G Voss; Goran Rakocevic; Mary McLaughlin; Carol L Vinton; Charles Huber; Xiaojun Hu; Jun Yang; Da Wei Huang; Carolea Logun; Robert L Danner; Zoila G Rangel; Peter J Munson; Jan M Orenstein; Elisabeth J Rushing; Richard A Lempicki; Marinos C Dalakas; Joseph A Kovacs
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

4.  In utero exposure of female CD-1 mice to AZT and/or 3TC: II. Persistence of functional alterations in cardiac tissue.

Authors:  Salina M Torres; Rao L Divi; Dale M Walker; Consuelo L McCash; Meghan M Carter; Matthew J Campen; Tracey L Einem; Yvonne Chu; Steven K Seilkop; Huining Kang; Miriam C Poirier; Vernon E Walker
Journal:  Cardiovasc Toxicol       Date:  2010-06       Impact factor: 3.231

5.  Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

Authors:  P Tebas; J Zhang; R Hafner; K Tashima; A Shevitz; K Yarasheski; B Berzins; S Owens; J Forand; S Evans; R Murphy
Journal:  J Antimicrob Chemother       Date:  2009-03-19       Impact factor: 5.790

6.  Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.

Authors:  Akihiko Saitoh; Terence Fenton; Carmelita Alvero; Courtney V Fletcher; Stephen A Spector
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

7.  PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.

Authors:  Tatsuyoshi Kawamura; Shannon E Bruse; Awet Abraha; Makoto Sugaya; Oliver Hartley; Robin E Offord; Eric J Arts; Peter A Zimmerman; Andrew Blauvelt; Shannon E Bruce
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.

Authors:  Salina M Torres; Dale M Walker; Consuelo L McCash; Meghan M Carter; Jessica Ming; Edmund M Cordova; Rachel M Pons; Dennis L Cook; Steven K Seilkop; William C Copeland; Vernon E Walker
Journal:  Environ Mol Mutagen       Date:  2009-01       Impact factor: 3.216

9.  Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.

Authors:  Allison Langs-Barlow; Lorna Renner; Karol Katz; Veronika Northrup; Elijah Paintsil
Journal:  AIDS Res Treat       Date:  2013-03-07

10.  Antiretroviral therapy-induced mitochondrial toxicity: potential mechanisms beyond polymerase-γ inhibition.

Authors:  S Selvaraj; M Ghebremichael; M Li; Y Foli; A Langs-Barlow; A Ogbuagu; L Barakat; E Tubridy; R Edifor; W Lam; Y-C Cheng; E Paintsil
Journal:  Clin Pharmacol Ther       Date:  2014-03-17       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.